Biomarkers in the Early Detection and Diagnosis of Alzheimer's Disease
DOI:
https://doi.org/10.12775/JEHS.2026.94.73121Keywords
Alzheimer's disease, biomarkers, early diagnosis, p-tau217, amyloid PET, optical coherence tomography, neurodegenerationAbstract
Background. Alzheimer's disease (AD) accounts for 60–70% of the over 57 million dementia cases worldwide and is projected to nearly triple by 2050. Neuropathology precedes symptoms by roughly two decades, and the approval of anti-amyloid therapies has made biomarker-confirmed early diagnosis a clinical priority.
Aim. This narrative review synthesizes evidence on cerebrospinal fluid (CSF), blood, neuroimaging, genetic, retinal, and emerging molecular biomarkers for early detection of AD, framed within the 2024 revised NIA-AA biological criteria.
Material and methods. PubMed, MEDLINE, Google Scholar, the Journal of Education, Health and Sport, and Quality in Sport were searched for studies and consensus documents published between 2014 and 2026. Six mandatory references were integrated with seventeen additional peer-reviewed sources.
Results. CSF Aβ42/40, total tau, and p-tau181 remain reference-standard markers. Plasma p-tau217 has emerged as the leading minimally invasive biomarker, with areas under the curve of 0.92–0.96 against amyloid PET. Serum neurofilament light and glial fibrillary acidic protein support staging and differential diagnosis. Amyloid and tau PET enable in vivo Braak staging; structural MRI tracks hippocampal atrophy. APOE ε4 genotyping has regained clinical relevance in the anti-amyloid era. Optical coherence tomography, metabolomics, microRNAs, and AI-driven multimodal models expand the diagnostic frontier.
Conclusions. AD can now be detected biologically before symptoms become disabling. Translating plasma assays and AI-supported imaging into routine practice is the central challenge of the coming decade.
References
1. World Health Organization. (2025, March 31). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia
2. Alzheimer’s Disease International. (2025, September 18). World Alzheimer Report 2025: Reimagining life with dementia – the power of rehabilitation. https://www.alzint.org/resource/world-alzheimer-report-2025/
3. Muller, C., Grodsky, E., Brickman, A. M., et al. (2025). Education and midlife cognitive functioning: Evidence from the High School and Beyond cohort. Alzheimer’s & Dementia, 21, e70015. https://doi.org/10.1002/alz.70015
4. Nichols, E., Steinmetz, J. D., Vollset, S. E., et al. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 7(2), e105–e125. https://doi.org/10.1016/S2468-2667(21)00249-8
5. Cichacz-Kwiatkowska, B., Sekita-Krzak, J., Kot-Bakiera, K., Jodłowska-Jędrych, B., & Wawryk-Gawda, E. (2016). Choroba Alzheimera – rola badań immunohistochemicznych w diagnostyce choroby (Alzheimer’s disease – the role of immunohistochemistry in the diagnosis of disease). Journal of Education, Health and Sport, 6(2), 122–137. https://apcz.umk.pl/JEHS/article/view/3380
6. Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
7. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20(8), 5143–5169. https://doi.org/10.1002/alz.13859
8. Strużek, K., Karamus, K., Rejmak, R., Borowska-Łygan, M., Urban, W., Tomaszewski, J., et al. (2025). Modern biomarkers as key tools in the early diagnosis and monitoring of Alzheimer’s disease progression. Journal of Education, Health and Sport, 80, 60238. https://doi.org/10.12775/JEHS.2025.80.60238
9. van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
10. Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., et al. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
11. Fang, T., Dai, Y., Hu, X., Xu, Y., & Qiao, J. (2024). Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer’s disease. Frontiers in Neurology, 15, 1320653. https://doi.org/10.3389/fneur.2024.1320653
12. Tarawneh, R., D’Angelo, G., Crimmins, D., Herries, E., Griest, T., Fagan, A. M., et al. (2016). Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurology, 73(5), 561–571. https://doi.org/10.1001/jamaneurol.2016.0086
13. Wajda, K., Mika, W., Słowik, J., & Sieradzka, I. (2025). The importance of metabolomics in research into pathological processes leading to neurodegenerative diseases. Journal of Education, Health and Sport, 85, 66541. https://doi.org/10.12775/JEHS.2025.85.66541
14. Szarpak, J., Dalmata, W., Gąbka, I., Madycka, D., & Wysokińska, O. (2020). The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer’s disease. Journal of Education, Health and Sport, 10(9), 308–318. https://doi.org/10.12775/JEHS.2020.10.09.035
15. d’Abramo, C., D’Adamio, L., & Giliberto, L. (2020). Significance of blood and cerebrospinal fluid biomarkers for Alzheimer’s disease: Sensitivity, specificity and potential for clinical use. Journal of Personalized Medicine, 10(3), 116. https://doi.org/10.3390/jpm10030116
16. Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., et al. (2024). Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology, 81(3), 255–263. https://doi.org/10.1001/jamaneurol.2023.5319
17.Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., et al. (2009). MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain, 132(4), 1067–1077. https://doi.org/10.1093/brain/awp007
18. Richards, D., & Sabbagh, M. N. (2014). Florbetaben for PET imaging of beta-amyloid plaques in the brain. Neurology and Therapy, 3(2), 79–88. https://doi.org/10.1007/s40120-014-0022-9
19. Macedo, A. C., Tissot, C., Therriault, J., Servaes, S., Wang, Y. T., Fernandez-Arias, J., et al. (2023). The use of tau PET to stage Alzheimer disease according to the Braak staging framework. Journal of Nuclear Medicine, 64(8), 1171–1178. https://doi.org/10.2967/jnumed.122.265200
20. Ritchie, M., Sajjadi, S. A., & Grill, J. D. (2024). Apolipoprotein E genetic testing in a new age of Alzheimer disease clinical practice. Neurology: Clinical Practice, 14(2), e200230. https://doi.org/10.1212/CPJ.0000000000200230
21. Wei, W., Wang, Z. Y., Ma, L. N., Zhang, T. T., Cao, Y., & Li, H. (2020). MicroRNAs in Alzheimer’s disease: Function and potential applications as diagnostic biomarkers. Frontiers in Molecular Neuroscience, 13, 160. https://doi.org/10.3389/fnmol.2020.00160
22. Król, A., Muraszewska, E., Muraszewski, Ł., Kwitowska, P., Ubysz, E., Lewandowska, E., et al. (2026). Optical coherence tomography (OCT) as a retinal biomarker for brain neurodegeneration: A narrative review. Quality in Sport, 54, 70115. https://doi.org/10.12775/QS.2026.54.70115
23. Rehan, D., Solisch, S., Blazhkova, A., Susłow, A., Szwed, A., & Szczęsna, E. (2025). Advancing Alzheimer’s diagnosis: The role of AI – a review. Journal of Education, Health and Sport, 77, 57093. https://doi.org/10.12775/JEHS.2025.77.57093
24. Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2025). Blood-based tau as a biomarker for early detection and monitoring of Alzheimer’s disease: A systematic review and meta-analysis. International Journal of Molecular Sciences, 26(21), 10330. https://doi.org/10.3390/ijms262110330
25. Suresh, S., Maffei, L., Bauermeister, S., & Raymont, V. (2025). Blood biomarkers for diagnosis & differential diagnosis of Alzheimer’s disease in real-world clinical populations: A systematic review. medRxiv. https://doi.org/10.1101/2025.07.06.25330840
26. Sari, C. P., Situmeang, R. F. V., & Meriyanti, T. (2024). Diagnostic accuracy of blood-based biomarkers for early detection of Alzheimer’s disease: A systematic review. https://doi.org/10.19166/lijn.v2i1.11078
27. Bhatia, V., Chandel, A., & Minhas, Y. (2025). Advances in biomarker discovery and diagnostics for Alzheimer’s disease. Neurological Sciences, 46, 2419–2436. https://doi.org/10.1007/s10072-025-08023-y
28. Afrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025). Advanced biomarkers: Beyond amyloid and tau: Emerging non-traditional biomarkers for Alzheimer’s disease diagnosis and progression. Ageing Research Reviews, 108, 102736. https://doi.org/10.1016/j.arr.2025.102736
29. Heneka, M. T., Gauthier, S., Chandekar, S. A., Hahn-Pedersen, J. H., Bentsen, M. A., & Zetterberg, H. (2025). Neuroinflammatory fluid biomarkers in patients with Alzheimer’s disease: A systematic literature review. Molecular Psychiatry, 30, 2783–2798. https://doi.org/10.1038/s41380-025-02939-9
30. Dubois, B., von Arnim, C. A. F., Burnie, N., et al. (2023). Biomarkers in Alzheimer’s disease: Role in early and differential diagnosis and recognition of atypical variants. Alzheimer’s Research & Therapy, 15(1), 175. https://doi.org/10.1186/s13195-023-01314-6
31. Leuzy, A., Mattsson-Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., Hansson, O., & Mattsson-Carlgren, N. (2022). Blood-based biomarkers for Alzheimer’s disease. EMBO Molecular Medicine, 14(1), e14408. https://doi.org/10.15252/emmm.202114408
32. Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639–652. https://doi.org/10.1038/s41582-018-0079-7
33. Pais, M. V., Forlenza, O. V., & Diniz, B. S. (2023). Plasma biomarkers of Alzheimer’s disease: A review of available assays, recent developments, and implications for clinical practice. Alzheimer’s Disease Reports, 7(1), 543–556. https://doi.org/10.3233/ADR-230029
34. Rani, S., Dhar, S. B., Khajuria, A., Singh, A., Sharma, N., & Kaur, G. (2023). Advanced overview of biomarkers and techniques for early diagnosis of Alzheimer’s disease. Cell Biochemistry and Biophysics, 81(4), 2491–2523. https://doi.org/10.1007/s10571-023-01330-y
35. Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., & Blennow, K. (2022). Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. The Lancet Neurology, 21(1), 66–77. https://doi.org/10.1016/S1474-4422(21)00361-6
36. Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., Schöll, M., Massarweh, G., Soucy, J.-P., Höglund, K., Brinkmalm, G., Mattsson-Carlgren, N., Palmqvist, S., Hansson, O., Blennow, K., & Zetterberg, H. (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology, 19(5), 422–433. https://doi.org/10.1016/S1474-4422(20)30071-5
37. Delaby, C., Hirtz, C., & Lehmann, S. (2023). Overview of the blood biomarkers in Alzheimer’s disease: Promises and challenges. Revue Neurologique, 179(3), 161–172. https://doi.org/10.1016/j.neurol.2022.09.003
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aleksandra Rucka, Mateusz Kowalski, Michał Rucki, Nikodem Cieleban, Maja Gajewska, Magdalena Modliborska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 98
Number of citations: 0
